114 related articles for article (PubMed ID: 15020845)
1. Oncogenic K-ras in mouse models of myeloproliferative disease and acute myeloid leukemia.
Chan IT; Gilliland DG
Cell Cycle; 2004 May; 3(5):536-7. PubMed ID: 15020845
[TBL] [Abstract][Full Text] [Related]
2. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.
Chan IT; Kutok JL; Williams IR; Cohen S; Kelly L; Shigematsu H; Johnson L; Akashi K; Tuveson DA; Jacks T; Gilliland DG
J Clin Invest; 2004 Feb; 113(4):528-38. PubMed ID: 14966562
[TBL] [Abstract][Full Text] [Related]
3. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.
Li Q; Haigis KM; McDaniel A; Harding-Theobald E; Kogan SC; Akagi K; Wong JC; Braun BS; Wolff L; Jacks T; Shannon K
Blood; 2011 Feb; 117(6):2022-32. PubMed ID: 21163920
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice.
Parikh C; Subrahmanyam R; Ren R
Blood; 2006 Oct; 108(7):2349-57. PubMed ID: 16763213
[TBL] [Abstract][Full Text] [Related]
5. Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals through K-Ras at the plasma membrane of acute myeloid leukemia cells.
Köthe S; Müller JP; Böhmer SA; Tschongov T; Fricke M; Koch S; Thiede C; Requardt RP; Rubio I; Böhmer FD
J Cell Sci; 2013 Oct; 126(Pt 20):4746-55. PubMed ID: 23943874
[TBL] [Abstract][Full Text] [Related]
6. Detection of N-RAS and K-RAS in their active GTP-bound form in acute myeloid leukemia without activating RAS mutations.
Ehmann F; Horn S; Garcia-Palma L; Wegner W; Fiedler W; Giehl K; Mayr GW; Jücker M
Leuk Lymphoma; 2006 Jul; 47(7):1387-91. PubMed ID: 16923573
[TBL] [Abstract][Full Text] [Related]
7. STAT3 supports experimental K-RasG12D-induced murine myeloproliferative neoplasms dependent on serine phosphorylation.
Gough DJ; Marié IJ; Lobry C; Aifantis I; Levy DE
Blood; 2014 Oct; 124(14):2252-61. PubMed ID: 25150294
[TBL] [Abstract][Full Text] [Related]
8. The New Clinicopathologic and Molecular Findings in Myeloid Neoplasms With inv(3)(q21q26)/t(3;3)(q21;q26.2).
Wang HY; Rashidi HH
Arch Pathol Lab Med; 2016 Dec; 140(12):1404-1410. PubMed ID: 27628325
[TBL] [Abstract][Full Text] [Related]
9. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.
Chang YI; You X; Kong G; Ranheim EA; Wang J; Du J; Liu Y; Zhou Y; Ryu MJ; Zhang J
Leukemia; 2015 Sep; 29(9):1847-56. PubMed ID: 25801914
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation.
Brendel C; Teichler S; Millahn A; Stiewe T; Krause M; Stabla K; Ross P; Huynh M; Illmer T; Mernberger M; Barckhausen C; Neubauer A
PLoS One; 2015; 10(4):e0123181. PubMed ID: 25901794
[TBL] [Abstract][Full Text] [Related]
11. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.
Braun BS; Tuveson DA; Kong N; Le DT; Kogan SC; Rozmus J; Le Beau MM; Jacks TE; Shannon KM
Proc Natl Acad Sci U S A; 2004 Jan; 101(2):597-602. PubMed ID: 14699048
[TBL] [Abstract][Full Text] [Related]
12. RALB provides critical survival signals downstream of Ras in acute myeloid leukemia.
Eckfeldt CE; Pomeroy EJ; Lee RD; Hazen KS; Lee LA; Moriarity BS; Largaespada DA
Oncotarget; 2016 Oct; 7(40):65147-65156. PubMed ID: 27556501
[TBL] [Abstract][Full Text] [Related]
13. Nf1 deficiency cooperates with oncogenic K-RAS to induce acute myeloid leukemia in mice.
Cutts BA; Sjogren AK; Andersson KM; Wahlstrom AM; Karlsson C; Swolin B; Bergo MO
Blood; 2009 Oct; 114(17):3629-32. PubMed ID: 19710506
[TBL] [Abstract][Full Text] [Related]
14. Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice.
MacKenzie KL; Dolnikov A; Millington M; Shounan Y; Symonds G
Blood; 1999 Mar; 93(6):2043-56. PubMed ID: 10068678
[TBL] [Abstract][Full Text] [Related]
15. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
[TBL] [Abstract][Full Text] [Related]
16. Preclinical efficacy of MEK inhibition in Nras-mutant AML.
Burgess MR; Hwang E; Firestone AJ; Huang T; Xu J; Zuber J; Bohin N; Wen T; Kogan SC; Haigis KM; Sampath D; Lowe S; Shannon K; Li Q
Blood; 2014 Dec; 124(26):3947-55. PubMed ID: 25361812
[TBL] [Abstract][Full Text] [Related]
17. Rce1 deficiency accelerates the development of K-RAS-induced myeloproliferative disease.
Wahlstrom AM; Cutts BA; Karlsson C; Andersson KM; Liu M; Sjogren AK; Swolin B; Young SG; Bergo MO
Blood; 2007 Jan; 109(2):763-8. PubMed ID: 16973961
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy.
Meyer M; Rübsamen D; Slany R; Illmer T; Stabla K; Roth P; Stiewe T; Eilers M; Neubauer A
PLoS One; 2009 Nov; 4(11):e7768. PubMed ID: 19890398
[TBL] [Abstract][Full Text] [Related]
19. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
[TBL] [Abstract][Full Text] [Related]
20. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples.
Shih LY; Liang DC; Huang CF; Chang YT; Lai CL; Lin TH; Yang CP; Hung IJ; Liu HC; Jaing TH; Wang LY; Yeh TC
Leukemia; 2008 Feb; 22(2):303-7. PubMed ID: 17960171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
